BGT007
Dual CAR‑T for solid tumors
Investigator‑initiated trialActive
Key Facts
About Biosyngen
Biosyngen builds first‑in‑class cell‑therapy platforms to treat solid‑tumor cancers with rapid, safe, and scalable manufacturing.
View full company profile